NEW YORK (GenomeWeb News) – Flow cytometry systems maker Accuri Cytometers has received $4 million in Series D financing from current and new investors, the company said today.
The Ann Arbor, Mich.-based firm said it plans to use the funds support manufacturing and marketing of its C6 Flow Cytometer and the CSampler, which is used to automate the C6.
This round of financing came from previous investors Fidelity Biosciences, Flagship Ventures, Baird Venture Partners, and Arboretum Ventures, and included an investment from InvestMichigan!, a program co-managed by Credit Suisse.
The company closed a $13 million Series C financing round in July 2008.
Accuri CEO Jennifer Baird said in a statement that the company plans to "build out our manufacturing and customer support capabilities in Michigan and to continue to expand our presence globally."